Blood Markers of Treatment-Related Brain Injury in Children With Brain Tumors
Looks for blood markers of brain injury from treatment in children with brain tumors.
Plain-language title generated from the registry record
Registry title: Biomarkers of Brain Injury in Children With Brain Tumors
Key facts
- Where
- Uppsala, SwedenSee the site
Where in Sweden
- Uppsala UniversityUppsala, SwedenTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Uppsala University
- Trial code
- NCT07381959
- Record updated
- 2 February 2026
- Original description
The goal of this observational study is to identify biomarkers of treatment-induced brain injury in children treated for primary brain tumors. The main question it aims to answer is:Read full original descriptionShow less
Biomarkörer för hjärnskada Hos Barn Med hjärntumör
The goal of this observational study is to identify biomarkers of treatment-induced brain injury in children treated for primary brain tumors. The main question it aims to answer is:
Can investigators identify sensitive plasma biomarker(s) of treatment-induced brain injury in children with primary brain tumors?
Researchers will compare results between different treatment modalities (surgery, chemotherapy, radiation versus radiation-naive) and a healthy age- and sex-matched control population, to identify treatment-specific biomarkers.
Participants will provide plasma samples at the following time points: before surgery, 1-2 weeks after surgery, as well as at 3-, 6-, 12-, 18-, 24-, and 36 months after surgery. Participants who receive radiation treatment will also provide plasma samples before and during treatment (approximately every 2 weeks). Where possible, plasma samples are also collected before the start of any new treatment (e.g., chemotherapy). Healthy controls will provide samples once.
Inclusion: Age 0-17 years old, AND; Diagnosed with primary brain tumor through surgery, biopsy, or other diagnostic method (e.g., for germinoma) at Uppsala University Hospital or at another university hospital in Sweden, AND; Referred for radiotherapy at Skandion Clinic in Uppsala and/or at their local hospital (in some cases), with/without the addition of other cancer treatments; Age 0-17 years old, AND; Diagnosed with primary brain tumor through surgery, biopsy, or other diagnostic method (e.g., for optic pathway glioma in neurofibromatosis type 1 and germinoma) at Uppsala University Hospital or at another university hospital in Sweden, AND; Not referred to radiotherapy and treated with/without the addition of other cancer treatments; Age 0-17 years old at time of recruitment.
Exclusion: Have diagnosis of chronic disease that requires continuous medication; Diagnosed with a tumor only in the spinal cord (solitary spinal tumor); Diagnosed with a tumor considered palliative already at diagnosis (e.g., diffuse intrinsic pontine glioma); Unable to provide informed consent due to language difficulties.